Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
about
Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient PharmaceuticalsEconomic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis.National trends in the ambulatory treatment of hypertension in the United States, 1997-2012.Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goalsAntihypertensive drugs for elderly patients: a cross- sectional study.Full coverage for hypertension drugs in rural communities in China.Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.Fixed-dose combinations for treatment of type 2 diabetes mellitus.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.Management of Hypertension in Primary Care Safety-Net Clinics in the United States: A Comparison of Community Health Centers and Private Physicians' Offices.Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy.
P2860
Q28550319-52278C96-45FD-4B24-A029-67137619FA77Q34646932-1435E51B-5704-4FA8-888D-90C0C93446F2Q35147255-6A5F4045-4EE9-49B2-B240-100C82F6F791Q35210540-F28D143C-7EB1-4517-82E0-8E2F45565C67Q35662172-2EB5EA19-E226-4EAD-8C60-B9D3E1DAE670Q35962302-A2FDEB5E-D483-4347-84C3-0E6E9AB9E698Q37427232-DF504E91-1474-4C3E-9258-320710AB1934Q37978206-E7A41B7F-DDF4-448E-BB1F-4EEE339E4B0FQ38046641-AAC9BC4D-3FE7-4994-B236-5602AB405678Q39117083-59C256D9-BBED-45A0-8354-752210F50284Q39695053-419E537D-9574-4127-8B13-130D69A64630Q40736954-C322197A-DF2E-4243-84E6-DAD610429B06Q44890659-D7B36035-699F-458A-B760-CB34F1963168
P2860
Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Out-of-pocket and total costs ...... tensives and their components.
@ast
Out-of-pocket and total costs ...... tensives and their components.
@en
Out-of-pocket and total costs ...... tensives and their components.
@nl
type
label
Out-of-pocket and total costs ...... tensives and their components.
@ast
Out-of-pocket and total costs ...... tensives and their components.
@en
Out-of-pocket and total costs ...... tensives and their components.
@nl
prefLabel
Out-of-pocket and total costs ...... tensives and their components.
@ast
Out-of-pocket and total costs ...... tensives and their components.
@en
Out-of-pocket and total costs ...... tensives and their components.
@nl
P356
P1476
Out-of-pocket and total costs ...... tensives and their components.
@en
P2093
Atonu Rabbani
G Caleb Alexander
P304
P356
10.1038/AJH.2008.31
P577
2008-03-20T00:00:00Z